Ole Schmeltz Søgaard, CROI 2022: eCLEAR study – The Impact of 3BNC117 and Romidepsin Treatment at ART Initiation on HIV-1 Persistence
The eCLEAR study (NCT03041012) safety findings in newly diagnosed HIV-1-infected adults are discussed in this video interview with Prof. Ole Schmeltz Søgaard (Aarhus University, Aarhus, Denmark). He discusses the findings from the eCLEAR study that evaluated the impact of the bNAb 3BNC117 and/or latency reversal with romidepsin (RMD) on HIV-1 persistence among individuals starting first-line INSTI-based ART regimens.
The abstract entitled: ‘The Impact Of 3BNC117 And Romidepsin Treatment at Art Initiation on HIV-1 Persistence’ (Abstract #479) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What were the aims and design of the eCLEAR study? (0:05)
- What were the outcome measures and how well were they achieved? (1:35)
- What was observed in your findings? (2:29)
Disclosures: Prof. Ole Schmeltz Søgaard has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Sunil Solomon, CROI 2023: Unknowns and hurdles surrounding long-acting injectable PrEP for the prevention of HIV
touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]
Sunil Solomon, CROI 2023: Current knowledge surrounding long-acting injectable PrEP for the prevention of HIV
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]
Nyaradzo Mgodi, CROI 2023: Long-acting injectable PrEP and cabotegravir roll-out for prevention of HIV- Factors affecting clinical practice and policy making
Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!